GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Return-on-Tangible-Asset

Tourmaline Bio (Tourmaline Bio) Return-on-Tangible-Asset : -18.70% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tourmaline Bio's annualized Net Income for the quarter that ended in Mar. 2024 was $-53.24 Mil. Tourmaline Bio's average total tangible assets for the quarter that ended in Mar. 2024 was $284.73 Mil. Therefore, Tourmaline Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -18.70%.

The historical rank and industry rank for Tourmaline Bio's Return-on-Tangible-Asset or its related term are showing as below:

TRML' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -426.06   Med: -232.23   Max: -16.91
Current: -16.91

During the past 3 years, Tourmaline Bio's highest Return-on-Tangible-Asset was -16.91%. The lowest was -426.06%. And the median was -232.23%.

TRML's Return-on-Tangible-Asset is ranked better than
68.99% of 1551 companies
in the Biotechnology industry
Industry Median: -39.81 vs TRML: -16.91

Tourmaline Bio Return-on-Tangible-Asset Historical Data

The historical data trend for Tourmaline Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Return-on-Tangible-Asset Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Return-on-Tangible-Asset
- -426.06 -38.40

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only -329.83 -70.43 -23.13 4.71 -18.70

Competitive Comparison of Tourmaline Bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, Tourmaline Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tourmaline Bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Return-on-Tangible-Asset falls into.



Tourmaline Bio Return-on-Tangible-Asset Calculation

Tourmaline Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-42.124/( (9.098+210.295)/ 2 )
=-42.124/109.6965
=-38.40 %

Tourmaline Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-53.244/( (210.295+359.169)/ 2 )
=-53.244/284.732
=-18.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Tourmaline Bio  (NAS:TRML) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Tourmaline Bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio (Tourmaline Bio) Business Description

Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.